Premium
Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients
Author(s) -
Strom Sara S.,
Gu Yun,
Zhang Hui,
Troncoso Patricia,
Babaian Richard J.,
Pettaway Curtis A.,
Shete Sanjay,
Spitz Margaret R.,
Logothetis Christopher J.
Publication year - 2004
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20060
Subject(s) - prostate cancer , androgen receptor , prostatectomy , medicine , proportional hazards model , oncology , androgen , hazard ratio , prospective cohort study , genotype , endocrinology , gynecology , cancer , biology , genetics , gene , hormone , confidence interval
Background Little is known about the role of inherited genotypes in prostate cancer (PC) progression. This prospective study evaluated the predictive value of androgen receptor (AR) polymorphisms (CAG and GGC repeats) among prostatectomy patients. Methods We studied 354 patients registered at M. D. Anderson Cancer Center from 1991 to 2001. Kaplan–Meier and Cox proportional hazard analyses were used. Results During an average follow‐up of 56 months, 66 (19%) post‐prostatectomy patients experienced biochemical failure (BF). Patients with higher CAG repeats (CAG ≥ 24) had significantly longer BF‐free survival (BFFS) than those with fewer repeats (CAG ≤ 23) ( P = 0.04). Higher CAG repeats were significantly associated with lower BF risk among Whites and African Americans. Among Whites, longer CAG repeats (relative risk (RR) = 0.45, P = 0.03) and Gleason score ≥8 (RR = 19.33, P = 0.005) remained significant BFFS predictors in multivariate analysis. GGC repeats were not associated with BF. Conclusions Our data showed that an inherited polymorphism (CAG repeats) in the AR is related to differences in genetic susceptibility to BF, supporting the hypothesis that increased AR activity may play a role in PC progression. © 2004 Wiley‐Liss, Inc.